Wolverine Asset Management LLC Nuvation Bio Inc. Transaction History

Wolverine Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 01, 2024	SELL	$0.96 - $1.53 $2,400 - $3,825	-2,500 Reduced 39.04%	3,904 $5,000
Q1 2023 May 08, 2023	BUY	$1.6 - $2.48 $3,484 - $5,401	2,178 Added 51.54%	6,404 $10,000
Q3 2022 Nov 10, 2022	BUY	$0.29 - $4.04 $127 - $1,777	440 Added 11.62%	4,226 $9,000
Q2 2022 Aug 03, 2022	BUY	$3.24 - $5.85 $1,490 - $2,691	460 Added 13.83%	3,786 $12,000
Q1 2022 May 04, 2022	BUY	$4.6 - $8.83 $2,373 - $4,556	516 Added 18.36%	3,326 $17,000
Q4 2021 Feb 09, 2022	SELL	$7.75 - $10.05 $3,394 - $4,401	-438 Reduced 13.49%	2,810 $23,000
Q3 2021 Nov 12, 2021	SELL	$7.78 - $10.0 $55,821 - $71,750	-7,175 Reduced 68.84%	3,248 $32,000
Q2 2021 Aug 13, 2021	BUY	$9.22 - $14.48 $89,157 - $140,021	9,670 Added 1284.2%	10,423 $97,000
Q1 2021 May 13, 2021	BUY	$9.0 - $14.57 $6,777 - $10,971	753 New	753 $7,000

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Asset Management LLC with notifications on news.